SI3519416T1 - Derivati kromana, izokromana in dihidroizobenzofurana kot mGluR2-negativni alosterični modulatorji, sestavki in njihova uporaba - Google Patents

Derivati kromana, izokromana in dihidroizobenzofurana kot mGluR2-negativni alosterični modulatorji, sestavki in njihova uporaba

Info

Publication number
SI3519416T1
SI3519416T1 SI201730727T SI201730727T SI3519416T1 SI 3519416 T1 SI3519416 T1 SI 3519416T1 SI 201730727 T SI201730727 T SI 201730727T SI 201730727 T SI201730727 T SI 201730727T SI 3519416 T1 SI3519416 T1 SI 3519416T1
Authority
SI
Slovenia
Prior art keywords
isochromane
mglur2
chromane
compositions
allosteric modulators
Prior art date
Application number
SI201730727T
Other languages
English (en)
Inventor
Iyassu K. Sebhat
Ashok Arasappan
Scott B. Hoyt
Robert R. Wilkening
Duane Demong
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of SI3519416T1 publication Critical patent/SI3519416T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SI201730727T 2016-09-27 2017-09-25 Derivati kromana, izokromana in dihidroizobenzofurana kot mGluR2-negativni alosterični modulatorji, sestavki in njihova uporaba SI3519416T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662400150P 2016-09-27 2016-09-27
PCT/US2017/053155 WO2018063955A1 (en) 2016-09-27 2017-09-25 CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
EP17781253.4A EP3519416B1 (en) 2016-09-27 2017-09-25 Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use

Publications (1)

Publication Number Publication Date
SI3519416T1 true SI3519416T1 (sl) 2021-08-31

Family

ID=60043302

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730727T SI3519416T1 (sl) 2016-09-27 2017-09-25 Derivati kromana, izokromana in dihidroizobenzofurana kot mGluR2-negativni alosterični modulatorji, sestavki in njihova uporaba

Country Status (39)

Country Link
US (4) US10335399B2 (sl)
EP (1) EP3519416B1 (sl)
JP (3) JP6681517B2 (sl)
KR (1) KR102296043B1 (sl)
CN (1) CN109983022B (sl)
AR (1) AR109714A1 (sl)
AU (2) AU2017334870C1 (sl)
CA (1) CA3037537C (sl)
CL (1) CL2019000778A1 (sl)
CO (1) CO2019002673A2 (sl)
CR (1) CR20190147A (sl)
CY (1) CY1124346T1 (sl)
DK (1) DK3519416T3 (sl)
DO (1) DOP2019000076A (sl)
EA (1) EA038627B1 (sl)
EC (1) ECSP19020742A (sl)
ES (1) ES2868973T3 (sl)
GE (2) GEP20217279B (sl)
HR (1) HRP20210793T1 (sl)
HU (1) HUE054898T2 (sl)
IL (1) IL265366B (sl)
JO (1) JOP20190058B1 (sl)
LT (1) LT3519416T (sl)
MA (1) MA46342B1 (sl)
MD (1) MD3519416T2 (sl)
MX (1) MX2019003492A (sl)
MY (1) MY196807A (sl)
NI (1) NI201900025A (sl)
PE (1) PE20190609A1 (sl)
PH (1) PH12019500597A1 (sl)
PL (1) PL3519416T3 (sl)
PT (1) PT3519416T (sl)
RS (1) RS61890B1 (sl)
SI (1) SI3519416T1 (sl)
TN (2) TN2020000160A1 (sl)
TW (1) TWI764934B (sl)
UA (1) UA123687C2 (sl)
WO (1) WO2018063955A1 (sl)
ZA (1) ZA201901701B (sl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190609A1 (es) * 2016-09-27 2019-04-23 Merck Sharp & Dohme DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTERICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
MA51620A (fr) 2018-01-19 2020-11-25 Cytokinetics Inc Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques
WO2020005887A1 (en) 2018-06-26 2020-01-02 Cytokinetics, Inc. Cardiac sarcomere inhibitors
SG11202109564UA (en) * 2019-03-01 2021-10-28 Kbp Biosciences Co Ltd Process for preparing a fused tricyclic compound, and intermediate thereof
AU2022229390A1 (en) 2021-03-04 2023-09-21 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2023278729A1 (en) * 2021-06-30 2023-01-05 The General Hospital Corporation Chromane imaging ligands

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552437A (en) 1994-10-27 1996-09-03 Merck Frosst Canada, Inc. Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
US5576338A (en) 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
JP2009510132A (ja) 2005-10-05 2009-03-12 メルク フロスト カナダ リミテツド ロイコトリエン生合成の阻害剤としての置換キノリン
AR065093A1 (es) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
BRPI0917394A2 (pt) 2008-08-18 2019-09-24 Univ Yale moduladores de mif
CN102439008B (zh) * 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-***并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
CA2784830C (en) 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
MY167423A (en) 2011-11-03 2018-08-27 Merck Sharp & Dohme Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
WO2016029454A1 (en) * 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
US9382208B1 (en) 2015-01-26 2016-07-05 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 2
US10538491B2 (en) 2015-03-16 2020-01-21 Vanderbilt University 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
JP6471614B2 (ja) 2015-05-29 2019-02-20 株式会社リコー 通信端末、通信システム、通信制御方法、及びプログラム
JP2018154554A (ja) 2015-07-29 2018-10-04 大日本住友製薬株式会社 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途
PE20190609A1 (es) * 2016-09-27 2019-04-23 Merck Sharp & Dohme DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTERICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO

Also Published As

Publication number Publication date
US10806724B2 (en) 2020-10-20
TN2020000160A1 (en) 2022-04-04
TWI764934B (zh) 2022-05-21
CR20190147A (es) 2019-05-17
CN109983022A (zh) 2019-07-05
ECSP19020742A (es) 2019-04-30
MD3519416T2 (ro) 2021-09-30
CO2019002673A2 (es) 2019-03-29
CA3037537C (en) 2021-06-15
JP6992109B2 (ja) 2022-02-15
PE20190609A1 (es) 2019-04-23
UA123687C2 (uk) 2021-05-12
PT3519416T (pt) 2021-05-13
GEP20217279B (en) 2021-08-10
MA46342B1 (fr) 2021-05-31
BR112019005869A2 (pt) 2019-06-11
IL265366A (en) 2019-05-30
NI201900025A (es) 2019-05-27
MY196807A (en) 2023-05-03
MA46342A (fr) 2019-08-07
CN109983022B (zh) 2022-06-07
KR20190056418A (ko) 2019-05-24
HUE054898T2 (hu) 2021-10-28
WO2018063955A1 (en) 2018-04-05
HRP20210793T1 (hr) 2021-09-03
AU2017334870B2 (en) 2020-08-20
JP2019529468A (ja) 2019-10-17
JP2020011989A (ja) 2020-01-23
IL265366B (en) 2021-12-01
BR112019005869A8 (pt) 2023-05-02
EP3519416A1 (en) 2019-08-07
JP2020111596A (ja) 2020-07-27
RS61890B1 (sr) 2021-06-30
GEP20217266B (en) 2021-06-25
LT3519416T (lt) 2021-06-10
AU2020270468B2 (en) 2022-02-17
TN2020000161A1 (en) 2022-04-04
CL2019000778A1 (es) 2019-05-31
PH12019500597A1 (en) 2019-07-24
CY1124346T1 (el) 2022-07-22
EP3519416B1 (en) 2021-03-31
JP6681517B2 (ja) 2020-04-15
EA038627B1 (ru) 2021-09-24
AU2020270468A1 (en) 2020-12-10
US20210015800A1 (en) 2021-01-21
CA3037537A1 (en) 2018-04-05
US10335399B2 (en) 2019-07-02
DOP2019000076A (es) 2019-07-15
JP6945605B2 (ja) 2021-10-06
EA201990818A1 (ru) 2019-08-30
MX2019003492A (es) 2019-09-19
KR102296043B1 (ko) 2021-08-30
JOP20190058B1 (ar) 2023-09-17
US20220218676A1 (en) 2022-07-14
US20190247374A1 (en) 2019-08-15
DK3519416T3 (da) 2021-05-25
US20180085358A1 (en) 2018-03-29
ES2868973T3 (es) 2021-10-22
TW201815794A (zh) 2018-05-01
AR109714A1 (es) 2019-01-16
ZA201901701B (en) 2023-03-29
PL3519416T3 (pl) 2021-09-06
AU2017334870C1 (en) 2020-12-17
JOP20190058A1 (ar) 2019-03-24
AU2017334870A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
HK1256608A1 (zh) 類黃酮組合物及其使用方法
ZA201901701B (en) Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use
EP3383447A4 (en) PHOTOACTIVATED PREPARATION OF HYDROGELS
EP3380096A4 (en) CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
EP3139920A4 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
EP3201187A4 (en) Compositions and methods for inhibiting bmp
EP3288553A4 (en) Combinations of cannabinoids and n-acylethanolamines
IL252311B (en) 4-oxo-4,3-dihydro-3,2,1-benzotriazines as G protein-coupled receptor modulators 139
EP3535252A4 (en) COMPOSITION COMPRISING A COMBINATION OF EPICATECHIN AND ANTI-CANCER COMPOUND
EP3122355A4 (en) Compositions and methods for inhibiting bmp
EP3472176A4 (en) THE USEFULNESS OF (+) EPICATECHIN AND THEIR ANALOGS
EP3185865A4 (en) TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
EP3355881A4 (en) ORAL TAXANE COMPOSITIONS AND RELATED METHODS
ZA201508973B (en) Chromane and chromene derivatives and their use as crac modulators
EP3111939A4 (en) Vitamin d and antibacterial uses of composition thereof
PL3468964T3 (pl) Modulatory soce, ich kompozycje i zastosowania
EP3512834A4 (en) INHIBIT OF BMP SIGNALING, CONNECTIONS, COMPOSITIONS AND USES THEREOF
EP3109242B8 (en) Water-soluble taxane derivatives and uses thereof
EP3277274A4 (en) Anti-methanogenic lovastatin analogs or derivatives and uses thereof
HK1257091A1 (zh) 茚烷衍生物作為mglur7調節劑
EP3201204A4 (en) C5-c6-fused tricyclic iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP3397627A4 (en) INDOLIZIN DERIVATIVES, COMPOSITION AND METHODS OF USE
EP3371192A4 (en) PODOPHYL LOTOXIN DERIVATIVES AND THEIR USE
IL259900A (en) Aminoazole derivatives, compositions containing same and uses thereof
AU2016902397A0 (en) Composition containing Proanthocyanidins